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Hongzhen Hu 2*
1Division of Basic Medical Sciences, Mercer University School of Medicine, Macon, GA, USA, 2Department of
Anesthesiology, The Center for the Study of Itch, Washington University School of Medicine in St. Louis, St. Louis, MO, USA
Transient receptor potential vanilloid receptor 4 (TRPV4) is a calcium-permeable
non-selective cation channel implicated in numerous physiological and pathological
functions. This study aimed to investigate the effect of TRPV4 activation on respiration
and to explore the potential involvement of bronchopulmonary sensory neurons.
Potent TRPV4 agonist GSK1016790A was injected into right atrium in anesthetized
spontaneously breathing rats and the changes in breathing were measured. Patch-clamp
recording was performed to investigate the effect of GSK1016790A or another
TRPV4 activator 4α-PDD on cultured rat vagal bronchopulmonary sensory neurons.
Immunohistochemistry was carried out to determine the TRPV4-expressing cells in lung
slices obtained from TRPV4-EGFP mice. Our results showed, that right-atrial injection
of GSK1016790A evoked a slow-developing, long-lasting rapid shallow breathing in
anesthetized rats. Activation of TRPV4 also significantly potentiated capsaicin-evoked
chemoreflex responses. The alteration in ventilation induced by GSK1016790A was
abolished by cutting or perineural capsaicin treatment of both vagi, indicating the
involvement of bronchopulmonary afferent neurons. The stimulating and sensitizing
effects of GSK1016790A were abolished by a selective TRPV4 antagonist GSK2193874
and also by inhibiting cyclooxygenase with indomethacin. Surprising, GSK1016790A
or 4α-PDD did not activate isolated bronchopulmonary sensory neurons, nor did
they modulate capsaicin-induced inward currents in these neurons. Furthermore,
TRPV4 expression was found in alveolar macrophages, alveolar epithelial, and vascular
endothelial cells. Collectively, our results suggest that GSK1016790A regulates the
respiration through an indirect activation of bronchopulmonary sensory neurons, likely
via its stimulation of other TRPV4-expressing cells in the lungs and airways.
Keywords: alveolar macrophage, bronchopulmonary sensory neuron, pulmonary chemoreflex, rapid shallow
breathing, transient receptor potential vanilloid receptor 4
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INTRODUCTION
Transient receptor potential vanilloid receptor 4 (TRPV4) is
a calcium-permeable non-selective cation channel that can be
activated by diverse stimuli including moderate heat, shear stress,
endogenous chemicals such as anandamide, arachidonic acid,
and its epoxyeicosatrienoic acid metabolites, as well as by a
growing number of exogenous chemical ligands such as 4α-
PDD and GSK1016790A (Vriens et al., 2004; Heller and O’Neil,
2007; Nilius and Voets, 2013). Growing evidence has shown
that TRPV4 is involved in numerous physiological functions
including body osmoregulation and noxious mechanical and
thermal sensation, and mutation in the TRPV4 gene is known to
cause skeletal dysplasia and neurodegenerative diseases (Heller
and O’Neil, 2007; Nilius and Voets, 2013; Garcia-Elias et al.,
2014). In the respiratory system, however, the function of TRPV4
is not well understood other than its involvement in acute lung
injury (Alvarez et al., 2006; Hamanaka et al., 2010; Balakrishna
et al., 2014).
Although, previous studies showed that the commonly
used TRPV4 activator 4α-PDD activates a majority of dorsal
root ganglion (DRG) neurons, a recent study questioned the
specificity of 4α-PDD and concluded that its effect on DRG
neurons is independent of TRPV4 activation (Alexander et al.,
2013). On the other hand, GSK1016790A is recently identified
as a selective TRPV4 channel agonist which is ∼300-fold
more potent than 4α-PDD (Thorneloe et al., 2008). In the
present study, we aimed to investigate the ventilatory effect
of GSK1016790A in anesthetized rats and further explore
the potential involvement of activation of bronchopulmonary
sensory neurons. Our results showed, that activation of TRPV4
may indirectly enhance the excitability of these neurons and
subsequently affect the respiration through chemoreflexes.
MATERIALS AND METHODS
The procedures described below were performed in compliance
with the Public Health Service Policy on Humane Care and Use
of Laboratory Animals (Office of Laboratory Animal Welfare,
Amended August, 2002) and U.S. Government Principles for
the Utilization and Care of Vertebrate Animals Used in Testing,
Research, and Training. These procedures were also approved
by the Institutional Animal Care and Use Committee of Mercer
University and Washington University.
Animal Preparation
Adult Sprague–Dawley rats were anesthetized with an intra-
peritoneal injection of α-chloralose (100mg/kg) and urethane
(500mg/kg) dissolved in a 2% borax solution. Supplemental
doses (one tenth of the initial dose) of the same anesthetics
were injected intravenously to maintain abolition of pain reflexes
induced by tail pinch. The left jugular venous catheter was
cannulated with its tip positioned slightly above the right atrium
for bolus injection of chemical stimuli. The left femoral artery was
cannulated for recording arterial blood pressure (ABP). In some
animals, the right femoral vein was also cannulated for infusion
of pharmacological agents. A short tracheal cannula was inserted
just below the larynx via a tracheotomy. Body temperature was
maintained at 37◦C throughout the experiment by means of
heating pad placed under the animal lying in a supine position. At
the end of experiment, animals were euthanized by intravenous
injection of an over dose of 3M KCl.
In-vivo Cardiopulmonary Recordings
Animals breathed spontaneously through the tracheal
cannula. Respiratory flow was measured by a differential
pressure transducer (HSE-HA DLP2.5, Harvard Apparatus,
Holliston, MA). Respiratory frequency (RF), tidal volume
(VT), expiratory duration (TE), ABP, and heart rate (HR) were
recorded and analyzed using PowerLab and LabChart Pro
from ADInstruments (Colorado Springs, CO). Pulmonary
chemoreflex responses were measured when intravenous
injections of capsaicin (0.75–1.25µg/kg), a selective transient
receptor potential vanilloid receptor 1 (TRPV1) agonist, were
administered. At least 15min was allowed to elapse between two
consecutive injections to avoid tachyphylaxis. To determine the
intensity of apneic response, the apneic ratio was calculated by
dividing the longest TE occurring within 3 s after the injection by
the baseline TE that was averaged over 10 breaths immediately
preceding the injection.
Retrograde Labeling of Vagal
Bronchopulmonary Sensory Neurons
Sensory neurons innervating airways and lungs were identified
by retrograde labeling using the fluorescent tracer 1,1′-
dioctadecyl-3,3,3′,3′-tetramethylindocarbocyanine perchlorate
(DiI), as described in our recent studies (Gu et al., 2013). Briefly,
young Sprague–Dawley rats (80–120 g) were anesthetized with
continuous inhalation of isoflurane administered via a nose cone
connected to a vaporizing machine (Smiths Medical, Dublin,
OH). A small mid-line incision was made on the ventral neck
skin to expose the trachea. DiI (0.2mg/ml, 50µl) was instilled
into the lungs via a 30-gage needle inserted into the lumen of
the trachea; the skin incision was then closed. Animals were kept
undisturbed for 7–10 days until they were used for tissue harvest.
Isolation of Nodose and Jugular Ganglion
Neurons
Rats were decapitated after being anesthetized by isoflurane
inhalation. The head was immediately immersed in ice-cold
Dulbecco’s modified Eagle’s medium (DMEM)/F12 solution,
followed by quick extraction of nodose and jugular ganglia under
a dissecting microscope. Each ganglion was desheathed, cut into
eight pieces, placed in a 0.08% type IV collagenase, and incubated
for 60min in 5% CO2 in air at 37
◦C. The ganglion suspension
was centrifuged (150 g, 5min) and supernatant aspirated. The
cell pellet was resuspended in 0.05% trypsin for 1min and
centrifuged (150 g, 5min); the pellet was then resuspended
in a modified DMEM/F12 solution (supplemented with 10%
heat-inactivated fetal bovine serum, 100 units/ml penicillin,
100µg/ml streptomycin, and 100µM minimum essential media
nonessential amino acids) and gently triturated with a small-bore
fire-polished Pasteur pipette. Myelin debris was separated and
discarded after centrifugation of the dispersed cell suspension
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(500 g, 8min) through a layer of 15% bovine serum albumin. The
cell pellet was resuspended in the modified DMEM/F12 solution,
plated onto poly-L-lysine-coated glass coverslips, and incubated
overnight (5% CO2 in air at 37
◦C).
Whole-Cell Perforated Patch-Clamp
Recordings
Whole-cell perforated (50µg/ml gramicidin) patch-clamp
recordings were carried out using Axopatch 200B, Digidata
1440A, and pCLAMP 10 software (Molecular Devices,
Sunnyvale, CA), as described previously (Gu et al., 2013).
The recording chamber with cultured cells was perfused
continuously with the standard extracellular solution (ECS)
containing in mM: 136 NaCl, 5.4 KCl, 1.8 CaCl2, 1 MgCl2, 0.33
NaH2PO4, 10 glucose, 10 HEPES, pH at 7.4. The intracellular
solution contained (in mM): 92 potassium gluconate, 40 KCl,
8 NaCl, 1 CaCl2, 0.5 MgCl2, 10 EGTA, 10 HEPES, pH at 7.2.
The chemical stimulants were applied by a pressure-driven drug
delivery system (VC38, ALA Scientific Instruments, Westbury,
NY). The resting membrane potential was held at −70mV. The
series resistance was usually in the range of 6–10 M and was
not compensated. The experiments were performed at room
temperature (∼22◦C). Data from nodose and jugular ganglion
neurons were pooled for group analysis since no difference was
found between responses of the neurons obtained from these
two ganglia.
Immunohistochemistry
Bacterial artificial chromosome (BAC)-transgenic Tg(TRPV4-
EGFP)MT43Gsat mice (designated as TRPV4eGFP) were
purchased from Mutant Mouse Resource Research Centers.
TRPV4-expressing cells were identified by expressing the eGFP
protein under control of the TRPV4 promoter (Gong et al.,
2003). Adult mice of 6–16 weeks were asphyxiated with CO2
and perfused transcardially with 200ml of 30% sucrose in 0.1M
phosphate buffer (PB; pH 7.3) followed by 200ml of fixative [4%
paraformaldehyde or Zamboni’s fixative (2% paraformaldehyde,
15% saturated picric acid) in 0.1M PB, pH 7.3]. The lungs were
removed and post-fixed overnight at 4◦C in the same fixative.
All tissues were cryoprotected overnight in 30% sucrose in 0.1M
PB, pH 7.3, frozen in optimal cutting temperature medium,
sectioned with a cryostat at 20µm, mounted on Superfrost Plus
slide, and stored at −20◦C. Frozen slides were dried at room
temperature for 1 h and washed three times in PBS with 0.1%
Triton X-100 (PBS+TX), blocked for 30min to 1 h in PBS+TX
containing 10% donkey serum, and incubated overnight at 4◦C
with primary antibodies diluted in blocking solution: chicken
anti-GFP (1:500; Aves Labs, Tigard, OR), and rat anti-F4/80
(1:500; Biolegend, San Diago, CA). The sections were then
washed three times in PBS+TX and incubated for 2 h at room
temperature with secondary antibodies conjugated to Alexa-488
fluorochrome (Life Technologies, Grand Island, NY) for chicken
anti-GFP or Cy3 fluorochromes (Jackson ImmunoResearch,
West Grove, PA) for rat anti-F4/80, and diluted 1:500 in blocking
solution. Sections were then washed three times in PBS+TX
and mounted with anti-fade medium Vectashield (Vector
Laboratories, Burlingame, CA). All preparations were examined
with Nikon A1 Confocal Laser Microscope System. Images were
taken and analyzed with Nikon NIS-Elements software.
Chemicals
All chemicals were purchased from Sigma-Aldrich (St. Louis,
MO). A stock solution of capsaicin (1mM) was prepared in
1% Tween 80, 1% ethanol, and 98% saline. Stock solutions
of GSK1016790A, 4α-PDD and GSK2193874 (10mM) were
prepared in dimethyl sulfoxide, aliquoted and kept at −80◦C.
Chemicals at desired concentrations were prepared daily by
dilution with isotonic saline in in-vivo studies or with ECS
in patch-clamp recordings. Indomethacin and Nω-nitro-L-
arginine methyl ester (L-NAME) were freshly prepared before
experiments in 0.1M NaHCO3 and isotonic saline, respectively.
No detectable effect of vehicles of chemical agents was found in
our preliminary experiments.
STATISTICAL ANALYSIS
One-way repeated-measure ANOVAwas used, unless mentioned
otherwise, for statistical analysis with SigmaPlot 12 (Systat
Software, San Jose, CA). When the ANOVA showed a significant
interaction, pair-wise comparisons were made with the Fisher’s
least significant difference post-hoc analysis. Data are presented
as the mean ± s.e.m. A value of p < 0.05 was considered to be
significant.
RESULTS
GSK1016790A Evoked Rapid Shallow
Breathing in Anesthetized Spontaneously
Breathing Rats
Right atrial injection of GSK1016790A did not induce a typical
apnea, but it evoked rapid shallow breathing that developed
rather slowly, peaked within 2min, and lasted up to 10min after
the injection (Figure 1). For example, 40µg/kg GSK1016790A
significantly increased the respiratory frequency from 62.7 ± 1.9
to 79.6 ± 3.2 breath per min and reduced tidal volume from 1.9
± 0.0 to 1.5 ± 0.1ml (n = 5; p < 0.01), whereas the minute
ventilation was not significantly altered after GSK1016790A (n =
5; p > 0.05; Table 1). At both 20 and 40µg/kg, GSK1016790A
also evoked a significant decrease in arterial blood pressure, and
increase in heart rate (Figure 1; Table 1).
GSK1016790A Potentiated
Capsaicin-Evoked Pulmonary
Chemo-Reflexes in Anesthetized Rats
Capsaicin is known to evoke apnea, bradycardia, and
hypotension through a stimulation of TRPV1 channels in
bronchopulmonary sensory neurons (Gu et al., 2005). At 15 and
30min after 40µg/kg GSK1016790A administration, when the
cardiopulmonary changes induced by GSK1016790A already
returned to baseline values, the capsaicin-evoked chemoreflexes
were significantly potentiated. The apneic ratio evoked by
capsaicin was increased from 3.1 ± 0.5 at control to 6.5 ± 0.9
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FIGURE 1 | Right atrial injection of GSK1016790A dose-dependently evoked rapid shallow breathing in anesthetized spontaneously breathing rats.
Injectate of GSK1016790A (0–40µg/kg in 0.15ml) was first slowly injected into the catheter (dead space volume 0.2ml) and then flushed (at arrow), as a bolus with
saline (0.3ml). Note that (A–C) were recorded from one animal, and (D) from another animal to show a clean recording. Flow, respiratory flow; RF, respiratory
frequency; ABP, arterial blood pressure; HR, heart rate; bpm, breath per minute.
Frontiers in Physiology | www.frontiersin.org 4 February 2016 | Volume 7 | Article 65
Gu et al. TRPV4-Mediated Regulation of Respiration
TABLE 1 | Cardiopulmonary effect of GSK1016790A in anesthetized rats.
Parameters Baseline GSK1016790A GSK1016790A GSK1016790A GSK1016790A
(n = 20) (vehicle; n = 5) (10µg/kg; n = 5) (20µg/kg; n = 5) (40µg/kg; n = 5)
RF (bpm) 62.7± 1.9 62.1± 5.2 63.3± 3.5 66.7± 3.8 79.6±3.2**
VT (ml) 1.9± 0.0 1.9± 0.1 1.9± 0.1 1.9± 0.1 1.5±0.1**
MV (ml/min) 116.2± 2.6 115.2± 7.8 117.5± 3.1 126.1± 3.0 115.8±4.4
ABP (mmHg) 126.7± 3.2 124.9± 6.8 127.9± 4.2 97.2± 10.0** 57.4±2.5**
HR (beats/min) 395.3± 9.1 382.5± 23.3 419.8± 6.4 433.8± 4.4* 431.4±11.5*
The baseline parameters were calculated as the average values over 20-s duration immediately before the injection of GSK1016790A; the parameters after GSK1016790A were
calculated as the average values over 20-s duration after the administration of GSK1016790A when changes in these parameters were the greatest from corresponding baseline values.
RF, respiratory frequency; VT , tidal volume; MV, minute ventilation; ABP, arterial blood pressure; HR, heart rate; bpm, breath per minute. *p < 0.05 and **p < 0.01, significantly different
from corresponding baseline values; Student’s t-test.
FIGURE 2 | Potentiation of capsaicin-evoked chemoreflexes by GSK1016790A in anesthetized rats. (A–C) Responses to right atrial injection of capsaicin
(1.0µg/kg) before, and 15 and 30min after administration of GSK1016790A (40µg/kg, i.v.). (D) Effect of GSK1016790A on the reflex apneic response to capsaicin
(0.75–1µg/kg). Apneic duration, longest expiratory duration within 3 s after injection of capsaicin; baseline TE, average expiratory duration over 10 consecutive
breaths immediately preceding the capsaicin injection. *Significantly different from the control response (n = 5; p < 0.05).
and 6.6 ± 0.7 at 15 and 30min after GSK1016790A, respectively,
(n = 5; p < 0.05; Figure 2).
TRPV4 Inhibition Prevented
Cardiopulmonary Effects of GSK1016790A
Systemic infusion of potent and selective TRPV4 antagonist
GSK2193874 (Thorneloe et al., 2012; 0.2mg/kg, 0.1ml/min for
30min) had no significant effect on baseline cardiopulmonary
values; however, it completely prevented the GSK1016790A-
induced changes in breathing, blood pressure, or heart rate,
as well as its potentiation of capsaicin-evoked chemoreflex
responses (n = 5; p > 0.05; Figure 3).
Involvement of Vagal Sensory Nerves in the
Ventilatory Effect of GSK1016790A
Cutting both vagi prevented the rapid shallow breathing (n =
5; p > 0.05), but not the hypotension (n = 5; p < 0.05)
evoked by 40µg/kg GSK1016790A. Not surprisingly, cutting
vagi completely abolished the capsaicin-evoked chemoreflexes
both before and after GSK1016790A (n = 5; p > 0.05;
Figures 4A–F). Similarly, both stimulating and sensitizing
effects of GSK1016790A on ventilation were also effectively
prevented with perineural capsaicin treatment of both vagi which
presumably blocks the conductance of bronchopulmonary C-
fibers (n = 4; Figures 4G,H), indicating the involvement of
activation of bronchopulmonary sensory afferents (Gu et al.,
2005).
Ventilatory Effect of GSK1016790A was
Abolished by Systemic Infusion of
Indomethacin but not L-NAME
It was reported previously, that the GSK1016790A-induced
relaxation of isolated vessels is probably endothelial/nitric oxide
dependent (Köhler et al., 2006; Willette et al., 2008). Systemic
constant infusion of 10mg/kg L-NAME (0.1ml/min for 30min),
a dose known to effectively inhibit nitric oxide synthesis in rats
(Badejo et al., 2008), was administered to test whether it affected
the observed cardiopulmonary effects of GSK1016790A in our
preparation. As expected, L-NAME infusion alone significantly
elevated arterial blood pressure and reduced heart rate (n =
5; p < 0.05; e.g., Figure 5D), while not affecting capsaicin-
evoked apneic responses (n = 5; p > 0.05; e.g., Figure 5E).
It did not inhibit 40µg/kg GSK1016790A-induced alterations in
breathing, blood pressure, or heart rate (n = 5; p < 0.05). L-
NAME also failed to abolish the potentiation of capsaicin-evoked
chemoreflexes by GSK1016790A (n = 5; p < 0.05; Figure 5).
On the other hand, infusion of indomethacin in the same
manner (10mg/kg, 0.1ml/min for 30min) which was known
to effectively inhibit the cyclooxygenase in anesthetized rat
preparation (Badzyn´ska et al., 2003), effectively prevented
both stimulating and sensitizing effects of GSK1016790A on
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FIGURE 3 | Cardiopulmonary effects of GSK1016790A were abolished by specific TRPV4 antagonist GSK2193874 in anesthetized rats. GSK2193874
(0.2mg/kg) was systemically infused for 30min at a constant rate of 0.1ml/min. GSK1016790A (40µg/kg) was administered at 15min after start of GSK2193874
infusion (A). Capsaicin-evoked chemoreflexes were recorded at control (B), and 15min after GSK1016790A administration (C). Group data show that GSK1016790A
did not induce significant change in RF, ABP, or HR (D), nor did its pretreatment alter the capsaicin-evoked apneic response (E), during GSK2193874 infusion (n = 5;
p > 0.05). Note, that to avoid tachyphylaxis, chemoreflexes evoked by capsaicin during GSK2193874 infusion, the middle column shown in (E), were carried out in
separate group of animals.
ventilation (n = 5; p > 0.05), while not affecting the
hypotension induced by GSK1016790A (n = 5; p <
0.05). Indomethacin alone did not significantly affect the
cardiopulmonary parameters, nor did it significantly alter
capsaicin-evoked apneic responses in these animals (n = 5;
p > 0.05; Figure 6).
TRPV4 is not Functionally Expressed in
Bronchopulmonary Sensory Neurons
Whole-cell perforated patch-clamp was carried out in isolated
rat bronchopulmonary sensory neurons. In 24 neurons obtained
from four different cultures including 16 capsaicin-sensitive
and 8 capsaicin-insensitive neurons, GSK1016790A (0.01–1µM,
8 s) failed to induce any whole-cell inward current (n = 24;
Figures 7A,B). In addition, pretreatment with GSK1016790A
(0.1 or 0.3µM, 60 s) did not significantly affect the capsaicin (0.1
or 0.3µM, 3–10 s) -evoked TRPV1 current (n = 10–16; p >
0.05; Figures 7C,D). Similarly, in a separate group of 16 neurons
including 11 capsaicin-sensitive and 5 capsaicin-insensitive ones,
the commonly used TRPV4 activator 4α-PDD (1–10µM, 8 s)
failed to induce any whole-cell current (n = 16), nor did its
pretreatment (3µM, 60 s) significantly alter the capsaicin (0.1 or
0.3µM, 3–10 s) -evoked inward current in these neurons (n =
11; p > 0.05; Figures 7E–H).
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FIGURE 4 | Cutting or perineural capsaicin treatment of both vagi effectively abolished effects of GSK1016790A on respiration in anesthetized rats. (A)
GSK1016790A (40µg/kg) injection after both vagi cut. (B–D) Capsaicin-evoked responses at control, before and 15min after GSK1016790A administration with vagi
cut. (E,F) Group data show GSK1016790A-induced changes in RF, ABP, HR, and capsaicin-evoked apneic response, respectively, before and after vagi cut. (G,H)
Group data show GSK1016790A-induced changes in RF, ABP, HR, and capsaicin-evoked apneic response, respectively, before and after bilateral perineural
capsaicin treatment (PNCT; 300µg/ml capsaicin). The latter was applied to both vagi 20min before GSK1016790A administration. *Significantly different from the
corresponding baseline control; #significantly different from corresponding values after vagi cut (n = 5; p < 0.05) or PNCT (n = 4; p < 0.05) alone.
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FIGURE 5 | Cardiopulmonary effects of GSK1016790A during systemic infusion of L-NAME in anesthetized rats. Nitric oxide synthesis inhibitor L-NAME
(10mg/kg) was constantly infused via a femoral vein at a rate of 0.1ml/min for 30min. GSK1016790A (40µg/kg) was administered at 15min after start of L-NAME
infusion (A). Capsaicin-evoked chemoreflexes were recorded at control (B), and 15min after GSK1016790A administration and right before the termination of
L-NAME infusion (C). Group data show GSK1016790A-induced changes in RF, ABP, and HR (D), and potentiation of capsaicin-evoked apneic response (E), during
L-NAME infusion. *Significantly different from the baseline control; #significantly different from values during L-NAME infusion (n = 5; p < 0.05).
Expression of TRPV4 in the Lung
We examined the TRPV4eGFP-expressing cells in the TRPV4
BAC-transgenic mice. Interestingly, the TRPV4eGFP is shown
in alveolar macrophages expressing a pan macrophage marker
F4/80. In addition, TRPV4 expression is also found in vascular
endothelial cells and alveolar epithelial cells shown inmouse lung
sections (Figure 8).
DISCUSSION
Our results showed that right atrial injection of GSK1016790A
induced rapid shallow breathing which developed slowly and
lasted up to 10min. GSK1016790A also had long-lasting
potentiating effect on capsaicin-evoked chemoreflexes. The
ventilatory effects of GSK1016790A were effectively prevented by
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FIGURE 6 | Effects of GSK1016790A on ventilation were inhibited by indomethacin in anesthetized rats. Cyclooxygenase inhibitor indomethacin (10mg/kg)
was constantly infused at a rate of 0.1ml/min for 30min. GSK1016790A (40µg/kg) was administered at 15min after start of indomethacin infusion (A).
Capsaicin-evoked chemoreflexes were recorded at control (B), and 15min after GSK1016790A administration (C). Group data show that GSK1016790A induced
hypotension and increase in heart rate (D), but not significant change in respiratory rate (D) or capsaicin-evoked apneic response (E), during indomethacin infusion.
*Significantly different from the baseline control; #significantly different from values during indomethacin infusion (n = 5; p < 0.05).
cutting or perineural capsaicin treatment of both vagi, indicating
involvement of bronchopulmonary sensory nerves. However, our
study showed that TRPV4 was not functionally expressed in
these sensory neurons, which is surprising considering TRPV4
mRNA and proteins were found in these neurons previously by
means of RT-PCR and immunohistochemistry (Ni et al., 2006).
Similarly, although expression and activation of TRPV4 in the
peripheral nervous system has long been implicated in thermal
and mechanical hyperalgesia as well as in pressure and heat
sensation (Todaka et al., 2004; Alessandri-Haber et al., 2006,
2008; Vergnolle et al., 2010; Chen et al., 2013), a recent study
by Alexander et al. (2013) questioned the existence of functional
TRPV4 channels in the vast majority of cultured DRG and
trigeminal ganglion neurons. The authors offered several possible
explanations for the discrepancy: (1) usage of non-selective
antibodies for TRPV4; (2) inappropriate usage of 4α-PDD as a
selective TRPV4 activator; and (3) misinterpretation of TRPV4
activity in non-neuronal cells as its neuronal function. Whether
these possibilities also attribute to the discrepancy between our
study and the previous report (Ni et al., 2006) is not yet clear.
Results of our patch-clamp study showed, that GSK1012790A
or 4α-PDD did not induce any inward current in isolated
capsaicin-sensitive or capsaicin-insensitive bronchopulmonary
sensory neurons, nor did these two TRPV4 activators affect
the TRPV1 current in capsaicin-sensitive neurons, suggesting
that TRPV4 is not functionally expressed in bronchopulmonary
afferents including unmyelinated C-fibers and myelinated
stretch receptors. The in-vivo cardiopulmonary effects of
GSK1016790A were mediated through activation of TRPV4 as
evidenced by a complete blockade by specific TRPV4 antagonist
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FIGURE 7 | TRPV4 is not functionally expressed in rat bronchopulmonary sensory neurons. (A,B) Show that GSK1016790A (0.01–1µM, 8 s) did not induce
any whole-cell inward current (n = 24). (C,D) Show, that pretreatment with GSK1016790A (0.1 or 0.3µM, 60 s) did not significantly affect the capsaicin-evoked
TRPV1 current (n = 10–16; p > 0.05). (E–H) Show that 4α-PDD (1–10µM, 8 s) did not induce any inward current (n = 16), nor did its pretreatment (3µM, 60 s)
significantly alter the capsaicin-evoked TRPV1 current (n = 11; p > 0.05).
FIGURE 8 | TRPV4-expressing cells in the lung. The TRPV4eGFP cells (A) expressed a pan macrophage marker F4/80 (B). The merged image (C) showed, that
TRPV4eGFP was also expressed by vascular endothelial cells (arrow head) and alveolar epithelial cells (arrow) in the mouse lung.
GSK2193874. Interestingly, both stimulatory and sensitizing
effects of GSK1016790A on ventilation were also effectively
prevented by systemic infusion of a non-selective cyclooxygenase
inhibitor indomethacin, indicating an involvement of some
inflammatory mediators downstream of cyclooxygenase pathway
including prostaglandins, prostacyclin and thromboxanes. Such
mediators such as prostaglandin E2 have been previously shown
to play an important role in regulating the excitability of
bronchopulmonary sensory terminals and inducing cough (Ho
et al., 2000; Gu et al., 2003; Maher et al., 2009). In addition,
all TRPV4-expressing cells in the lungs shown in our study,
including macrophages, epithelial, and endothelial cells, are
known to be cell sources for release of prostaglandins upon
stimulation (Liu et al., 2007; Profita et al., 2010; Giles et al., 2012).
The effects of TRPV4 activation on breathing shown in
our study seems consistent with the effects of stimuli that
evoke bronchoconstriction, which in turn would activate rapidly
adapting stretch recpeotrs (Chou et al., 2008). A recent
study using isometric tension measurements in ex-vivo airways
showed, that activation of TRPV4 by GSK1016790A caused
human airway constriction (McAlexander et al., 2014). The
authors further suggested that the constriction was dependent
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upon the production of cysteinyl leukotrienes, probably from
mast cells situated near the bronchial smooth muscle. This
latter finding could reflect a species difference though since
leukotrienes such as leukotriene C4 and leukotriene D4 are
known not to regulate rat airway smooth muscle (Henry et al.,
1992). An alternate explanation for the changes in respiration
induced by TRPV4 activation is that it could simply being
driven by the pulmonary edema elicited by GSK1016790A.
However, the study by Willette et al. (2008) seems argue
against this hypothesis because although GSK1016790A at
a high dose of 0.3mg/kg/15min caused drastic pulmonary
edema and congestion associated with perivascular and alveolar
hemorrhage, such abnormalities were not detected when a dose
of GSK1016790A (30–100µg/kg, i.v.) comparable to what we
used in this study was administered.
TRPV4 has been identified recently as an important player
in ventilator- and chemical-induced acute lung injury. It is
suggested, that TRPV4-mediated Ca2+-influx into alveolar
epithelial and vascular endothelial cells contributes to barrier
disruption and pulmonary edema (Alvarez et al., 2006). The
hypothesis was further supported by findings that TRPV4
inhibitor suppressed acid-induced pulmonary inflammation
by diminishing neutrophils, macrophages, and associated
chemokines and cytokines, while improving tissue pathology;
these effects were recapitulated in TRPV4-deficient mice
(Balakrishna et al., 2014). Studies on ventilator-induced lung
injury suggested that TRPV4 channels in alveolar macrophages
are crucial for induction of injury since activation of TRPV4
with 4α-PDD significantly increased intracellular calcium,
superoxide, and nitric oxide production in TRPV4+/+ but
not TRPV4−/− macrophages, while TRPV4+/+ macrophages
restored susceptibility of TRPV4−/− lungs to mechanical injury
(Hamanaka et al., 2010). Macrophages are the main resident
inflammatory cells in airways and lungs (Balhara and Gounni,
2012). In allergic asthma, drastic airway infiltration of eosinophils
as well as macrophages and other inflammatory cells has been
well documented (Gough et al., 2003; Ulrich et al., 2008). It
is therefore tempting to speculate that activation of TRPV4
channels in alveolar macrophages might lead to hypersensitivity
of bronchopulmonary sensory terminals. Thus, a given level of
stimulus may evoke a greater afferent discharge and consequently
a more severe airway constriction via both central cholinergic
pathway and local axon reflex (Lee and Pisarri, 2001). Indeed,
symptoms known to involve activation of these sensory endings,
such as cough, airway irritation, hypersecretion of mucus, and
reflex bronchoconstriction, are commonly reported in asthmatic
patients. Whether this TRPV4-mediated neural and immune
interaction indeed plays a role in the pathogenesis of asthma
remains to be investigated.
Our study showed, that intravenous injection of
GSK1016790A does-dependently induced hypotension
in anesthetized rats which was completely abolished by
GSK2193874. The vascular effects of TRPV4 activation have
been investigated previously. In isolated rat carotid artery
(Köhler et al., 2006) or in isolated mouse or rat aorta (Willette
et al., 2008), activation of TRPV4 induces endothelia/nitric
oxide-dependent relaxation. However, neither this endothelial
nitric oxide generation nor the cyclooxygenase prostaglandin
seems to play a major role in TRPV4-mediated hypotensive
effect in our study since the latter was not significantly affected
by systemic infusion of nitric oxide synthesis inhibitor L-NAME
or cyclooxygenase inhibitor indomethacin. Using 4α-PDD as the
TRPV4 activator, a recent study suggested that the depressor
effect of TRPV4 activation attributes to, at least in part, activation
of large conductance calcium-activated potassium channels in
resistant vessels and calcitonin gene related peptide receptors
upon the release of this peptide from sensory nerves (Gao and
Wang, 2010).
In summary, our results suggest that GSK1016790A
regulates the respiration through an indirect activation of
bronchopulmonary sensory neurons, likely via its stimulation of
other TRPV4-expressing cells in the lungs and airways.
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